SCHEMBL13664213

SCHEMBL13664213

N#Cc1c(C(=O)c2ccco2)nn(-c2ccc(Cl)cc2)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 2/20 0.44
KDM4E B2RXH2 1/20 0.42
PTGS2 P35354 1/20 0.41
LMNA P02545 3/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
PTGS1 P23219 1/20 0.40
CNR1 P21554 1/20 0.40
RECQL P46063 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40
MCL1 Q07820 1/20 0.40
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664174 0.81 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664212 0.81 MAPT (0.48) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664229 0.80 MAPT (0.48) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664223 0.79 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664230 0.79 MAPT (0.52) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664182 0.78 MAPT (0.51) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664224 0.78 MAPT (0.51) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664246 0.78 MAPT (0.48) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664217 0.78 MAPT (0.49) MAPTKMT2AMEN1SMN1; SMN2POLB
SCHEMBL13664177 0.77 MAPT (0.50) MAPTKMT2AMEN1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253673-A1 Substituted Pyrazoles as Ghrelin Receptor Antagonists GIPR, GPR119, GLP1R MAPT 4701/4885KMT2A 3722/4885MEN1 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.